Effectiveness of Autologous Fat Transfer in the Treatment of Scar-Related Conditions: A Systematic Review and Meta-analysis.

Aesthetic plastic surgery 2022 Vol.46(5) p. 2564-2572

Al Qurashi AA, Siddiqi AK, Alghamdi AA, Aljalfan AAN, Almenhali AA, Al Jabr FA, Rashid AM, Almas T, Menezes RG

관련 도메인

Abstract

[BACKGROUND AND AIM] Autologous fat transfer (AFT) has been introduced as a potential treatment option for scar-tissue and its related symptoms. However, the scientific evidence for its effectiveness remains unclear. This meta-analysis aims to evaluate the available evidence regarding the effectiveness of autologous fat transfer for the treatment of scar-tissue and its related conditions.

[METHODS] PubMed/Medline database was queried from its inception till the end of November 2021. All the relevant studies assessing the effect of autologous fat transfer in the treatment of scar-related conditions were pooled in using a random-effects model.

[RESULTS] 9 studies (n=179) were included in the meta-analysis. Pooled analysis demonstrates significant improvement in all subscales of the POSAS patient score with most prominent in color 2.4 points (95% CI 1.78-3.041), stiffness 2.9 points (95% CI 2.33-3.45), irregularity 2.2 points (95% CI 1.093-3.297) and thickness 1.8 points (95% CI 0.804-2.719), respectively. Pain and itch improved relatively lesser, 1.3 points (95% CI 0.958-1.674) and 0.6 points (95% CI 0.169-1.215), respectively. The POSAS observer scale showed a relatively lower improvement with the least in vascularity 0.5 points (95% CI 0.098-0.96), pigmentation 0.8 points (95% CI 0.391-1.276) and surface area 0.8 points (95% CI 0.34-1.25). Thickness improved by 1.4 points (95% CI 0.582-2.3), relief 1.0 points (95% CI 0.461-1.545) and pliability 1.5 points (95% CI 1.039-2.036).

[CONCLUSION] Our findings demonstrate that autologous fat transfer (AFT) is a promising treatment for scar-related conditions as it provides beneficial results in the scar quality. Future research should focus on the long-term effects of AFT and high-level evidence studies such as, randomized controlled trials (RCTs) and cohort studies are required.

[LEVEL OF EVIDENCE III] This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
해부 Fat scispacy 1
합병증 scar scispacy 1
합병증 pigmentation 색소침착 dict 1
약물 [BACKGROUND AND AIM scispacy 1
약물 [RESULTS] 9 scispacy 1
약물 CI 2.33-3.45 scispacy 1
약물 CI 0.804-2.719 scispacy 1
약물 CI 0.391-1.276 scispacy 1
약물 CI 0.582 scispacy 1
약물 CI 0.461-1.545 scispacy 1
약물 CI 1.039-2.036 scispacy 1
질환 scar-related scispacy 1
질환 Pain C0030193
Pain
scispacy 1
질환 itch C0033774
Pruritus
scispacy 1
질환 scar-tissue scispacy 1
기타 patient scispacy 1
기타 CI 1.093-3.297 scispacy 1

MeSH Terms

Humans; Cicatrix; Transplantation, Autologous; Cohort Studies; Treatment Outcome

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문